Prostatic Artery Embolization Offers Lasting Benefit for BPH

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 3, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 3, 2024 -- For men with benign prostatic hyperplasia (BPH), prostatic artery embolization (PAE) is safe and effective over 24 months of follow-up, according to a study published online Sept. 4 in Cardiovascular and Interventional Radiology.

Marc R. Sapoval, M.D., Ph.D., from the Assistance Publique-Hôpitaux de Paris, and colleagues conducted an international trial of men with BPH with lower urinary tract symptoms (LUTS) or acute urinary retention (AUR) treated with PAE. Clinical outcomes were described over 24 months, with the primary outcome of 12-month change in the International Prostate Symptom Score (IPSS) or urinary catheter independence for patients referred for bothersome LUTS and treated for AUR, respectively.

The analyses included 478 patients who underwent PAE (405 with bothersome LUTS and 73 with AUR). The researchers found that the mean total IPSS at baseline was 21.8 for patients treated for bothersome LUTS, which significantly decreased to 9.3, 10.6, and 11.2 at three, 12, and 24 months after PAE, respectively. At baseline, quality of life (QoL) was 4.7 and decreased to 2.0, 2.1, and 2.3 at three, 12, and 24 months, respectively. The mean Sexual Health Inventory for Men score was 13.8 and 13.9 at baseline and 12 months following PAE, respectively. Overall, 65.8 percent of the patients treated for AUR had their indwelling catheter removed within three months of PAE and remained catheter-free at 24 months. Overall, 11.5 percent experienced one or more adverse events, and 2.1 percent experienced a serious adverse event.

"The mean changes in IPSS and QoL scores suggest durability of the clinical benefits associated with PAE," the authors write.

Several authors disclosed ties to pharmaceutical and medical device companies, including Merit Medical Systems, which funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-04 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords